Development of drugs for gastrointestinal motor disorders: Translating science to clinical need

Keyphrases

• Irritable Bowel Syndrome 100%
• New Drugs 100%
• Gastrointestinal 100%
• Motor Disorders 100%
• Functional Dyspepsia 100%
• Motility 66%
• Gastrointestinal Diseases 66%
• Etiology 33%
• Clinical Outcomes 33%
• Disease-related 33%
• Glucose Control 33%
• Non-selective 33%
• Adrenoceptors 33%
• Patient Demographics 33%
• Diabetic 33%
• Receptor Activation 33%
• A1 Receptor 33%
• Co-agonist 33%
• Small Patients 33%
• Microbiota 33%
• Pharmacodynamic Properties 33%
• Receptor Selectivity 33%
• Constipation 33%
• 5-HT3 Antagonist 33%
• Stress-related 33%
• Functional Bowel Disorders 33%
• Selective Ligands 33%
• Antidiarrheal 33%
• Alosetron 33%
• Channel Activator 33%
• Tegaserod 33%
• D2 Antagonist 33%
• Guanylyl Cyclase C 33%
• Metoclopramide 33%
• Lubiprostone 33%
• 5-HT4 Agonist 33%
• New Biology 33%
• 5-HT4 Receptor 33%
• CRF1 33%
• Motilin Receptor 33%
• ClC-2 Chloride Channel 33%
• 5-HT4 Receptor Agonist 33%
• Ghrelin Receptor 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Irritable Colon 100%
• Gastrointestinal Motility Disorder 100%
• Stomach Acid 100%
• Pharmacodynamics 33%
• Receptor Agonist 33%
• Diabetes Mellitus 33%
• Gastrointestinal Symptom 33%
• Enteropathy 33%
• Adrenergic Receptor 33%
• Serotonin 3 Antagonist 33%
• Gastrointestinal Disease 33%
• Constipation 33%
• Microflora 33%
• Guanylate Cyclase 33%
• Antidiarrheal Agent 33%
• Alosetron 33%
• Metoclopramide 33%
• Tegaserod 33%
• Lubiprostone 33%
• Serotonin 4 Agonist 33%
• Ghrelin Receptor 33%
• Motilin Receptor 33%
• Corticotropin Releasing Factor Receptor 1 33%
• Diseases 33%